CytomX Therapeutics, Inc. ( CTMX ) NASDAQ Global Select

Cena: 2.12 ( -1.62% )

Aktualizacja 06-24 20:26
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 120
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98%
Ilość akcji: 66 988 900
Debiut giełdowy: 2015-10-08
WWW: https://www.cytomx.com
CEO: Dr. Sean A. McCarthy DPHIL
Adres: 151 Oyster Point Boulevard
Siedziba: 94080 South San Francisco
ISIN: US23284F1057
Opis firmy:

Cytomx Therapeutics, Inc. działa jako firma biofarmaceutyczna zorientowana na onkologę w Stanach Zjednoczonych. Firma opracowuje terapeutyki przeciwciał oparte na platformie technologii probodycznej do leczenia raka. Kandydaci na produkty firmy to CX-2009, koniugaty leku przeciwciał (ADC) przeciwko CD166, który jest w badaniach klinicznych fazy II w leczeniu raka piersi; CX-2029, który jest w badaniach klinicznych fazy II w leczeniu płaskonabłonkowego raka płuc, raka płaskonabłonkowego, głowa i szyi, raka płaskonabłonkowego, przełyku i nowotworów złącza przełyku i rozproszenia dużego chłoniaka z komórek B; BMS-986249, leku terapeutyczna probodyczna CTLA-4, który jest w fazie I/II badań klinicznych w leczeniu czerniaka z przerzutami; i BMS-986288, leek Probody anty-CTLA-4, który jest w badaniach klinicznych fazy I w leczeniu guzów litych. Opracowuje również CX-2043, warunkowo aktywowane ADC ukierunkowane na cząsteczkę adhezji komórek nabłonkowych, a także CX-904, warunkowo aktywowany receptor naskórkowego czynnika wzrostu do leczenia guza litego. Firma prowadzi strategiczną współpracę z Abbvie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Immunogen, Inc., Pfizer Inc. i Astellas Pharma Inc. w celu opracowania terapeutyków probody. Cytomx Therapeutics, Inc. został założony w 2008 roku i ma siedzibę w South San Francisco w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 334 781 000
Aktywa: 138 981 000
Cena: 2.12
Wskaźnik Altman Z-Score: -5.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: 4.4
Ilość akcji w obrocie: 98%
Średni wolumen: 5 012 108
Ilość akcji 157 544 000
Wskaźniki finansowe
Przychody TTM 126 617 000
Zobowiązania: 162 433 000
Przedział 52 tyg.: 0.4 - 3.095
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: 0.5
P/E branży: 26.1
Beta: 1.061
Raport okresowy: 2025-08-07
WWW: https://www.cytomx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Hoyoung Huh M.D., Ph.D. Special Advisor to Chief Executive Officer 72 500 1969
Dr. Marcia P. Belvin Ph.D. Senior Vice President & Chief Scientific Officer 634 827 0
Mr. Lloyd A. Rowland Jr., J.D. Senior Vice President, General Counsel, Chief Compliance Officer & Secretary 608 718 1957
Mr. Jeffrey Landau B.S., M.B.A. Senior Vice President, Head of Strategy & Chief Business Officer 580 692 1979
Dr. Sean A. McCarthy DPHIL Chairman & Chief Executive Officer 1 028 987 1967
Mr. Christopher W. Ogden Chief Financial Officer 0 1984
Ms. Danielle Olander-Moghadassian Senior Vice President & Chief Human Resources Officer 0 0
Dr. Yu-Waye Chu M.D. Chief Medical Officer 0 1968
Ms. Dawn Benson Senior Vice President of Quality & Product Manufacturing 0 0
Ms. Leslie Robbins Senior Vice President of Intellectual Property 0 0
Wiadomości dla CytomX Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. globenewswire.com 2025-02-27 10:00:00 Czytaj oryginał (ang.)
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2025-01-07 15:16:29 Czytaj oryginał (ang.)
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 - globenewswire.com 2025-01-06 18:05:00 Czytaj oryginał (ang.)
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com 2024-12-16 12:57:26 Czytaj oryginał (ang.)
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET. globenewswire.com 2024-11-27 10:00:00 Czytaj oryginał (ang.)
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2024-11-19 12:35:39 Czytaj oryginał (ang.)
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Participants Joseph Catanzaro - Piper Sandler Liang Cheng - Jefferies Etzer Darout - BMO Capital Markets Anupam Rama - J.P. seekingalpha.com 2024-11-08 10:44:12 Czytaj oryginał (ang.)
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year ago. zacks.com 2024-11-07 20:56:57 Czytaj oryginał (ang.)
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - globenewswire.com 2024-11-07 18:10:00 Czytaj oryginał (ang.)
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors. globenewswire.com 2024-09-09 12:00:00 Czytaj oryginał (ang.)
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - globenewswire.com 2024-08-08 20:10:00 Czytaj oryginał (ang.)
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. globenewswire.com 2024-06-18 12:00:00 Czytaj oryginał (ang.)
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. globenewswire.com 2024-06-17 20:15:00 Czytaj oryginał (ang.)
Buy Alert: 3 Penny Stocks That Will Explode in 2024 When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience. investorplace.com 2024-06-05 10:00:00 Czytaj oryginał (ang.)
No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock. Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back. investorplace.com 2024-05-29 10:25:00 Czytaj oryginał (ang.)
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET. globenewswire.com 2024-05-22 20:05:00 Czytaj oryginał (ang.)
CytomX Therapeutics Announces New Employment Inducement Grants SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. globenewswire.com 2024-05-16 20:15:00 Czytaj oryginał (ang.)
Why Is CytomX (CTMX) Stock Down 43% Today? CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical trail update covers its Phase 1a study of CX-904. investorplace.com 2024-05-09 15:56:41 Czytaj oryginał (ang.)
CytomX stock down 30% despite encouraging cancer study results CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing. invezz.com 2024-05-09 13:10:16 Czytaj oryginał (ang.)
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - globenewswire.com 2024-05-08 20:10:00 Czytaj oryginał (ang.)